BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1)

R Wäsch; J Hasskarl; D Schnerch; M Lübbert

doi:10.1007/978-3-642-01222-8_15

BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1)

Recent Results Cancer Res. 2010:184:215-8. doi: 10.1007/978-3-642-01222-8_15.

Authors

R Wäsch¹, J Hasskarl, D Schnerch, M Lübbert

Affiliation

¹ Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany. ralph.waesch@uniklinik-freiburg.de

PMID: 20072841
DOI: 10.1007/978-3-642-01222-8_15

Abstract

Human Polo-like kinase 1 (Plk1) is an essential regulator of mitotic progression. Targeted inhibition of this kinase was effective in killing tumor cells in vitro and in vivo. The Plk1 inhibitor BI_2536 was well tolerated and showed antitumor activity in the first clinical trials enrolling patients with advanced solid tumors and refractory or relapsed acute myeloid leukemia.

Publication types

Review

MeSH terms

Animals
Cell Cycle Proteins / antagonists & inhibitors*
Clinical Trials as Topic
Humans
Neoplasms / drug therapy*
Polo-Like Kinase 1
Protein Kinase Inhibitors / therapeutic use*
Protein Serine-Threonine Kinases / antagonists & inhibitors*
Proto-Oncogene Proteins / antagonists & inhibitors*
Pteridines / pharmacology
Pteridines / therapeutic use*

Substances

BI 2536
Cell Cycle Proteins
Protein Kinase Inhibitors
Proto-Oncogene Proteins
Pteridines
Protein Serine-Threonine Kinases